In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clarins

This article was originally published in The Rose Sheet

Executive Summary

David Yurman beauty and fragrance products will launch under a partnership between the fine jewelry company and Clarins Groupe USA, French beauty firm announces Oct. 5. Items will be positioned as prestige offerings, with the first fragrance launching principally in the U.S. and Canada, company says. Yurman's "distinct identity and strong brand values" make it the "ideal platform for the launch of unique fragrances," Clarins notes. The jewelry firm adds the partnership is a good fit due to the companies' shared commitment to maintaining brand integrity. The deal is the latest in a string of luxury fragrance partnerships, including BeautyBank and bag designer Coach and Inter Parfums and fine jewelry marketer Van Cleef & Arpels (1"The Rose Sheet" Sept. 25, 2006, Marketing in Brief and 2"The Rose Sheet" Oct. 9, 2006, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel